Optimising Treatment in Myelofibrosis Lead to Greater Benefits

At the recent 19th Malaysian Society of Haematology Scientific Meeting 2022, Professor Dr Martin Griesshammer presented an overview of the current paradigm surrounding myelofibrosis (MF) treatment and evidence that points to earlier initiation with JAK inhibition being beneficial for intermediate-1 patients.